Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies - CRVS News | RalliesCorvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies
C
CRVS• Corvus highlights soquelitinib pipeline updates
- Corvus Pharmaceuticals highlighted soquelitinib, an oral, highly selective ITK inhibitor positioned to rebalance immune responses across inflammatory pathways.
- Pipeline update centered on a Phase 3 peripheral T-cell lymphoma program that is enrolling, with a futility analysis targeted for Q1 2027.
- Atopic dermatitis program advanced into Phase 2 enrollment, following placebo-controlled Phase 1 results showing efficacy signals with 200 mg BID dosing.
- Phase 2 asthma study planned to start in 2H 2026; Phase 1b hidradenitis suppurativa study planned to start in September.
- China partnership with Angel Pharma includes ongoing PTCL and atopic dermatitis studies, with data expected in late 2026 and Q2 2027.
VIA
•
